Novavax, Inc. (NASDAQ:NVAX), said Wednesday it has raised $115 million in gross proceeds by selling 28.75 million shares of its common stock, which the Gaithersburg biotech plans to pour into its pipeline. Novavax, Inc. (NASDAQ:NVAX), weekly performance is 0.66%. On last trading day company shares ended up $4.55. Analysts mean target price for the company is $11.00. Novavax, Inc. (NASDAQ:NVAX), distance from 50-day simple moving average (SMA50) is 5.40%.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)’s shares gained 10.16% to $1.03. The company on May 15 provided an overview of its three clinical development programs and financial results for the quarter ended March 31, 2014. Rexahn’s cash and investments totaled $40.3 million as of March 31, 2014, compared to $19.0 million as of December 31, 2013. Rexahn’s net loss was $14.6 million, or $0.09 per share, for the first quarter of 2014, compared to a net loss of $1.5 million, or $0.01 per share, for the comparable period in 2013. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), advanced 3.82% in last trading session and ended the day on $0.971. RNN, return on assets is -62.50%. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), quarterly performance is -21.08%.
Shares of anti-obesity pill manufcaturer Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), rallied more than 4% in after hours session on Wednesday after an interview with CEO Jack Lief on CNBC. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), shares moved up 3.72% in last trading session and was closed at $6.41, while trading in range of $6.31 – 6.47. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), year to date (YTD) performance is 9.57%.
Gilead Sciences, Inc. (NASDAQ:GILD), generated $2.3 billion in Sovaldi sales – about half of the company’s total revenues – in the first quarter of its 2014 fiscal year. Gilead’s share price increased 1.2% yesterday on the positive news to close at $82.55. The screening will likely lead to an increase in the rate of diagnosis for the hepatitis C virus, which is known to have the potential to linger without symptoms in an individual’s body until it manifests into cancer and organ failure. Gilead Sciences, Inc. (NASDAQ:GILD), ended the last trading day at $80.58. Company weekly volatility is calculated as 2.38% and price to cash ratio as 19.13. Gilead Sciences, Inc. (NASDAQ:GILD), showed a negative weekly performance of 2.68%.
Galena Biopharma Inc (NASDAQ:GALE), reported the gain of +11.20%, to close at $2.68 with the overall traded volume of 5.12 million shares. The 52-week range for the stock is $1.65 and $7.77 and during the previous trading session the stock was found to mark $2.71 as its peak price. It kicked off the trading day with $2.34. Galena Biopharma Inc (NASDAQ:GALE), net profit margin is 7.00% and weekly performance is -4.50%. On last trading day company shares ended up $34.80. Analysts mean target price for the company is $34.27. Galena Biopharma Inc (NASDAQ:GALE), distance from 50-day simple moving average (SMA50) is -2.75%.
Leave a Reply